Annick Desjardins

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

John Sampson, Allan H Friedman, A. Friedman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recurrent Glioblastoma Treated with Recombinant Poliovirus

John H. Sampson, Katherine B. Peters, Darell D. Bigner, 2018, The New England journal of medicine.

A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors

John H. Sampson, Anthony F. Waller, Darell D. Bigner, 2011, PloS one.

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

Darell D. Bigner, Allan H. Friedman, Jeremy N. Rich, 2007, Clinical Cancer Research.

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Allan H Friedman, R. McLendon, A. Friedman, 2009, Neuro-oncology.

Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma

R. McLendon, H. Friedman, D. Reardon, 2009, Cancer.

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Yiting Cao, Mark W Dewhirst, M. Dewhirst, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecularly targeted therapy for malignant glioma

D. Reardon, A. Desjardins, J. Vredenburgh, 2007, Cancer.

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Allan H Friedman, James M Provenzale, R. McLendon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Allan H Friedman, R. McLendon, A. Friedman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.